Olesya Vasilyeva

Dr. Olesya Vasilyeva

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2015 in European Journal of Mass Spectrometry
Verified
Journal Article
Closed access
LGL.N. Gall
L.N. Gall
NFN.S. Fomina
N.S. Fomina
RGR. Giles
R. Giles
SMS.V. Masukevich
S.V. Masukevich
OVOlesya Vasilyeva
Olesya Vasilyeva
NGN.R. Gall
N.R. Gall
Electrospray ionization with controlled in-source fragmentation and atomization (ERIAD) is promising method for mass-spectrometric elemental analysis. This paper concerns the main analytical features and necessary instrumentation for ERIAD. The method is shown to be effective for more than 70 elements of the periodic table: those that present as cations in a water solution. It shows a high absolute sensitivity with a low spread from Li to U, and a detection limit of tens of parts per trillion. The soft ionization used results in the absence of plasma chemical reaction products, typical for inductively coupled plasma mass spectrometry, and the spectra are nearly free from interferences. The method does not require a high resolution and can be used for samples with an artificial isotopic content. The method is essentially valid for radiochemistry and metallomics, as it has the possibility to combine measurements of chemical, elemental, and even isotopic content simultaneously.

22 July 2024 in Reviews on Clinical Pharmacology and Drug Therapy
Verified
Journal Article
Open access
OVOlesya Vasilyeva
Olesya Vasilyeva
DKDmitrii Al. Kachanov
Dmitrii Al. Kachanov
ASAlexander Nikolaevich Stukov
Alexander Nikolaevich Stukov
GTGrigory Viktorovich Tochilnikov
Grigory Viktorovich Tochilnikov
APAndrey Vladislavovich Pavlysh
Andrey Vladislavovich Pavlysh
БМБеляев Алексей Михайлович
Беляев Алексей Михайлович
Currently, the targeted delivery of anticancer drugs can significantly increase the effectiveness of therapy, reduce the side effects of systemic chemotherapy, and improve the quality of patients with cancer. This review aimed to summarize data about the domestic antitumor drug 2,4-bis(1-aziridinyl)-6-(2,2-dimethyl-5-hydroxymethyl-1,3-dioxan-5-yl)amino-1,3,5-thriazine (dioxadet), its nanoforms, possibilities of its use in the clinic, and main antitumor nanodrugs clinically introduced in recent years. Library databases (eLibrary, PubMed, CyberLeninka, ResearchGate, Springer, Wiley Online Library, and Elsevier) were searched for relevant information. The literature review summarizes data on the preclinical trials of dioxadet and provides information on its nanoforms, such as nanogels, nanodiamonds, silica particles, and copolymers with lactic and caproic acids. New drug nanoforms open up opportunities to reduce drug side effects and systemic toxicity, maintain optimal therapeutic concentrations, increase the drug circulation time in the blood, and control its release. The possibility of using chemopreparation cytotoxic doses is the main advantage of new nanodrugs. To date, approximately 20 antitumor nanodrugs have been introduced in clinical practice, and some nanodrugs are undergoing preclinical trials or are in various phases of clinical trials. Thus, the development of a new effective nanoform, i.e., dioxadet, makes it possible to ensure targeted drug delivery in higher cytotoxic doses to target cells, increase selective action, and reduce cytostatic toxicity to normal cells.

15 December 2014 in Journal of obstetrics and women's diseases
Verified
Journal Article
Open access
PDF file
EVEkaterina Alexandrovna Vyshinskaya
Ekaterina Alexandrovna Vyshinskaya
VBVladimir Grigorievich Bespalov
Vladimir Grigorievich Bespalov
IVIrina Nikolaevna Vasilyeva
Irina Nikolaevna Vasilyeva
ASAlexander Semenov
Alexander Semenov
ASAlexander Nikolaevich Stukov
Alexander Nikolaevich Stukov
ABAlexey Mikhaylovich Belyaev
Alexey Mikhaylovich Belyaev
The purpose of research is a comparison of the combined antitumor effects of cytotoxic drugs used in the treatment of ovarian cancer, when administered intraperitoneally, with the effects of these drugs in mono-treatment. The study was conducted in 132 Wistar female rats inoculated intraperitoneally with ascitic tumor of the ovary. At 48 hours after inoculation of the ovarian tumor rats were administered once intraperitoneally with drugs at maximum tolerated doses, dioxadet 1.5 mg/kg of body weight, cisplatin 4 mg/kg, cyclophosphamide 100 mg/kg, paclitaxel 5 mg/kg, gemcitabine 50 mg/kg, or a combination of these drugs in half doses. Antitumor effects of the treatment were estimated by increase in survival time comparing median survival time of rats in different groups. Combinations dioxadet with cisplatin”, dioxadet with cyclophosphamide, and dioxadet with paclitaxel” have additive antitumor effects in comparison with the effects of these drugs administered separately. Combination dioxadet with gemcitabine did not increase the antitumor activity of the drugs.

30 December 2025 in Voprosy onkologii
Verified
Journal Article
Open access
OVOlesya Vasilyeva
Olesya Vasilyeva
ЕКЕкатерина Ярославовна Каданцева
Екатерина Ярославовна Каданцева
AGAlexandr Garanin
Alexandr Garanin
LZLidia Zabegina
Lidia Zabegina
ДСДмитрий Александрович Суров
Дмитрий Александрович Суров
Anastasia MalekAnastasia Malek
Anastasia Malek
Введение. Эффективность системной цитостатической терапии онкологических заболеваний, включая рак яичников, ограничена токсическим повреждением здоровых тканей. Разработка технологий адресной доставки противоопухолевых препаратов является актуальной задачей. Одна из перспективных стратегий решения этой задачи является разработка инновационных систем доставки на основе внеклеточных нановезикул (ВНВ), модифицированных ДНК-аптамерами. Цель. Разработка технологии модификации везикулярной мембраны ДНК-аптамером и оценка эффективности разработанной системы адресной доставки доксорубицина в клетки рака яичников in vitro. Материалы и методы. В исследовании были использованы образцы ткани перитонеальных метастазов рака яичников (n=3) и клеточные линии Skov-3 и Ovcar-3. ВНВ были выделены из плазмы здоровых доноров и исследованы с помощью анализа траекторий наночастиц (АТН) и проточной цитометрии. «Загрузка» доксорубицина (ДОКС) во ВНВ проводилась по разработанной ранее технологии сонопорации, очистка полученных комплексов ДОКС-ВНВ была проведена с помощью гель-фильтрации. Модификация везикулярной поверхности комплексов ДОКС-ВНВ, осуществлялась за счет гидрофобного взаимодействия мембраны с холестеролом, ковалентно связанным с молекулой ДНК-аптамера. Оценка цитотоксичности разработанной системы доставки доксорубицина проведена с помощью МТТ-теста. Результаты. На первом этапе исследования по литературным данным были выбраны кандидатные аптамеры, проведена оценка их связывания с клетками рака яичника и выбран наиболее аффинный аптамер. На втором этапе исследования была разработана везикулярная система доставки доксорубицина, включаяющая: получение ВНВ из плазмы доноров методом ультра-центрифугирования, «загрузку» доксорубицина во ВНВ с помощью сонопорации, очистку полученных комплексов (ДОКС-ВНВ) от свободного доксорубицина с помощью гель-фильтрации и получение комплексов ДОКС-ВНВ-АПТ путем модификации поверхности ВНВ аптамером. В ходе заключительного этапа исследования проведен анализ цитотоксичности разработанной системы доставки ДОКС-ВНВ-АПТ, которая оказалась существенно выше цитотоксичности системы ДОКС-ВНВ (1% vs 57% выживших клеток линии Scov-3, 0.03% vs 0,3% выживших клеток линии Ovcar-3). Выводы. Наличие специфичного аптамера, конъюгированного с везикулярной поверхностью, повышало эффективность везикулярной системы доставки цитостатического препарата к клеткам рака яичников в условиях in vitro эксперимента. Разработка системы доставки противоопухолевых препаратов на основе ВНВ, модифицированных ДНК-аптамерами, представляется перспективной стратегией повышения эффективности системной химиотерапии.

15 June 2014 in Journal of obstetrics and women's diseases
Verified
Journal Article
Open access
PDF file
YVYekaterina Aleksandrovna Vyshinskaya
Yekaterina Aleksandrovna Vyshinskaya
VBVladimir Grigoryevich Bespalov
Vladimir Grigoryevich Bespalov
IVIrina Nikolayevna Vasilyeva
Irina Nikolayevna Vasilyeva
ASAlexander Semenov
Alexander Semenov
ASAleksandr Nikolayevich Stukov
Aleksandr Nikolayevich Stukov
ABAleksey Mikhaylovich Belyayev
Aleksey Mikhaylovich Belyayev
The purpose of the study is to compare antitumor activity of different drugs at their Intraperitoneal (i. p.) and intravenous (i.v.) administration in rats with ovarian cancer peritoneal carcinomatosis. The study was carried out in 124 Wistar female rats with ovarian cancer which was inoculated i. p. After ovarian cancer inoculation rats were randomized in 12 groups, 10 rats in each group. There were six groups where saline (2 ml, i.p. control group) or the drugs (dioxadet 1.5 mg/kg, cisplatin 4mg/kg, mitomycin C 1.5 mg/kg, melphalan 2 mg/kg, paclitaxel 5 mg/kg) were administered i. p. In other six groups saline (2 ml, i. v. control group) and the named above drugs at the same doses were administered i. v. Antitumor effects of the treatment were estimated by increase in survival time (IST) comparing median survival time of rats in different groups. IST for i.p. administration of dioxadet, cisplatin, melphalan, mitomycin C and paclitaxel were 79 % (p < 0.001), 88 % (p < 0.001), 114 % (p < 0.001), 35 % (p < 0.002) and 45 % (p < 0.001) correspondingly compared to i.p. control group while for i.v. administration of these drugs IST were 5 % (p = 0.796), 14 % (p = 0.315), 19 % (p = 0.631), 152 % (p < 0.001) and 81 % (p = 0.023) correspondingly compared to i. v. control group. Thus, i. p. chemotherapy with alkylating agents dioxadet, cisplatin and melphalan is much more effective then their i. v. administration, while antitumor effects of i. p. and i. v. administration of paclitaxel were similar and only mitomycin C is more active at i. v. administration.

25 January 2025 in Pharmacokinetics and Pharmacodynamics
Verified
Journal Article
Open access
PDF file
ВАВ. А. Александров
В. А. Александров
GTG. V. Tochilnikov
G. V. Tochilnikov
SSS. V. Shatik
S. V. Shatik
ASA. N. Stukov
A. N. Stukov
OVOlesya Vasilyeva
Olesya Vasilyeva
TST. Yu. Semiglazova
T. Yu. Semiglazova
Background. The domestic antitumor compound 2-[3-(2-chloroethyl)-3-nitrosoureido]-1,3-propanediol (chlonisol) has high antitumor activity on a wide range of experimental tumors.Goal. To study the content of chlonisol in the blood of rats at different times after intravenous administration and its chemical stability in 0.9 % sodium chloride solution, urine and blood serum.Methods. The concentration of chlonisol in various media was determined by HPLC. In vivo studies on 10 male rats with a body weight of 180–200 g. the concentration of chlonisol in the blood of rats was determined 2, 30, 60, 90 and 120 minutes after its intravenous administration at a dose of 40 mg/kg. In in vitro experiments, a 0.1 % solution of chlonisol was incubated at 37 °C in three media: 0.9 % sodium chloride solution, blood serum and urine. Aliquots were selected at different intervals and analyzed for the content of chlonisol. The stability of chlonisol was evaluated in relation to its concentration before and after incubation, expressed as a percentage.Results. When chlonisol was administered intravenously at a dose of 40 mg/kg to rats, its complete disappearance from the blood was observed within 2 hours. The half-life was 27 minutes. Of the three media studied in vitro experiments, chlonisol was the most stable in 0.9 % sodium chloride solution(89 % of the initial level after 10 hours of incubation at 37 °C). Less stable, but for a long time – in urine (60 % of the initial after 1 hour of incubation and 37 % after 2 hours). The lowest resistance of chlonisol was in the blood serum (a decrease in concentration to 11 % after 1 hour and to 0 after 2 hours of incubation).Conclusion. The results obtained allow us to make assumptions about possible ways of using chlonisol: The high stability of chlonisol in 0.9 % sodium chloride solution will allow its long-term drip intravenous infusions, as well as perfusion intraarterial chemotherapy. Maintaining the concentration of chlonisol in urine at 60 % of the initial level for 1 hour will allow the use of intravesical instillations of chlonisol in superficial bladder cancer.